Product logins

Find logins to all Clarivate products below.


Venous thromboembolism | Disease Landscape & Forecast | G7 | 2023

Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus. It consists of deep vein thrombosis (DVT) and pulmonary embolism (PE), depending on the location of the obstruction. Pharmacological treatment of patients diagnosed with VTE consists mainly of anticoagulant therapy and, in some severe cases, thrombolytics. Patients at high risk of VTE receive primary prophylaxis with anticoagulants. These patients include hospitalized medically ill patients, patients undergoing orthopedic surgery or non-orthopedic surgery, and cancer patients. In recent years, new oral anticoagulants (NOACs) have become more widely used and have driven the growth of the VTE market. These drugs are being investigated to broaden their target population and to cover specific segments, while emerging therapies in the VTE pipeline include Novartis’s abemaciclib and Bayer’s osocimab (both are human monoclonal antibodies), Bristol Myers Squibb’s milvexian, Translational Sciences’ TS23, and Ionis’s fesomersen.

Questions answered

  • What are the key drivers and goals of VTE treatment? How do current therapies perform on these goals?
  • What do key opinion leaders think about Novartis’s abemaciclib, Bayer’s osocimab, Bristol Myers Squibb’s milvexian, Translational Sciences’ TS23, and Ionis’s fesomersen?
  • Will label expansions and genericization affect the market?
  • What are the key unmet needs in VTE, and how likely are they to be met?

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancements

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Related Market Assessment Reports

Report
Thyroid Eye Disease – Executive Insights – Thyroid Eye Disease | Executive Insights (US)
Report
Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms: Claims Data Analysis – IBS-Constipation (Including IBS Without Diarrhea) (US)
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is classified into three subtypes:…
Report
Uterine Fibroids – Current Treatment – Treatment Algorithms: Claims Data Analysis – Uterine Fibroids (US)
Treatment for uterine fibroids includes pharmacological approaches and surgical procedures. NSAIDs help alleviate the pain but do not reduce the fibroids’ size. Progestins (e.g., norethindrone,…
Report
Amyotrophic Lateral Sclerosis – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Amyotrophic lateral sclerosis (ALS) is a disorder of the central nervous system characterized by motor neuron degeneration. ALS causes progressive weakness and atrophy of the muscles and loss of…
Report
Kidney Transplant – Current Treatment – Treatment Algorithms: Claims Data Analysis – Kidney Transplant (US)
Each year in the United States, thousands of patients with end-stage renal disease undergo a kidney transplant. To prevent rejection and maintain the new kidney’s functionality, patients must…